We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Solventum to Report Q2 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
Solventum's Q2 results may show strength across MedSurg, Dental and Health Information Systems.
SOLV's $100M-plus in advance ERP orders may lift Q2 sales, with the benefit expected to reverse mainly in Q3.
Acera gains and productivity savings may support margins despite persistent tariff-related headwinds.
Solventum (SOLV - Free Report) is scheduled to release second-quarter 2026 results on Aug. 5, after market close. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 9.63%. SOLV delivered a trailing four-quarter average earnings surprise of 8.94%.
Solventum Q2 Estimates
Currently, the Zacks Consensus Estimate for second-quarter revenues is pegged at $2.17 billion. The consensus mark for second-quarter earnings is pinned at $1.91 per share.
Solventum’s second-quarter performance is expected to have reflected continued strength in its commercial execution across the MedSurg, Dental and Health Information Systems segments. Contributions from the Acera acquisition and ongoing cost-saving initiatives are also likely to support results.
Reported revenues are expected to have benefited from more than $100 million of advanced customer orders ahead of the planned U.S. ERP cutover in the third quarter. However, management stated that this represents a timing shift rather than incremental demand, with the benefit expected to reverse mainly in the third quarter. The company maintained its full-year guidance despite the sales phasing.
Tariff-related headwinds are expected to remain a drag. Nonetheless, savings from the Transform for the Future program and other productivity initiatives are likely to have supported margin expansion.
Segmental Overview
Solventum’s MedSurg segment is expected to have maintained healthy momentum in the second quarter. Growth is likely to have been driven by Advanced Wound Care, supported by continued demand for negative pressure wound therapy, including V.A.C. Peel and Place Dressing. The Acera acquisition is also expected to have contributed to reported growth as integration progresses. Infection Prevention and Surgical Solutions is likely to have benefited from strong demand for Tegaderm CHG and recent sterilization product launches. Reported growth may also have been aided by customer orders pulled forward ahead of the planned U.S. ERP cutover.
The Dental Solutions business is expected to have delivered another solid quarter. Performance is likely to have been supported by continued demand for the Clarity portfolio, Filtek Easy Match and Clinpro Clear products, along with stronger commercial execution and improved product availability. Similar to Infection Prevention, reported sales are also expected to have benefited from advanced customer orders ahead of the planned U.S. ERP cutover.
The Health Information Systems segment is expected to have continued its steady growth trajectory. Demand for Revenue Cycle Management solutions and increasing adoption of autonomous coding are likely to have remained key growth drivers. The company's international expansion and healthy backlog conversion are also expected to have supported segment performance. Weakness in Clinician Productivity Solutions is likely to have remained a partial offset.
On the operational front, investors are likely to watch progress on the company's separation from 3M and the upcoming U.S. ERP cutover. Management expects more than $100 million of sales to shift into the second quarter due to advance customer orders, with the benefit reversing mainly in the third quarter. Meanwhile, tariff headwinds are expected to persist. Even so, savings from the Transform for the Future program, portfolio optimization initiatives and productivity improvements are expected to continue supporting margins.
Earnings Beat Unlikely
Our proven model does not predict an earnings beat for Solventum this time around. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP:Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% for Solventum.
You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank:Solventum currently has a Zacks Rank #2.
Here are some stocks worth considering from the broader medical sector, as these have the right combination of elements to post an earnings beat this reporting cycle.
CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter earnings per share (EPS) indicates an improvement of 16.4% from the year-ago reported figure.
Cencora (COR - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank of 2 at present. The company is scheduled to release third-quarter fiscal 2026 results on Aug. 5.
COR’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 1.59%. The Zacks Consensus Estimate for COR’s fiscal third-quarter EPS implies an improvement of 9.3% from the year-ago reported figure.
Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank #2 at present.
A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS calls for an improvement of 8% from the year-ago reported figure.
View the Zacks #1 Rank List
Image: Bigstock
Solventum to Report Q2 Earnings: What's in Store for the Stock?
Key Takeaways
Solventum (SOLV - Free Report) is scheduled to release second-quarter 2026 results on Aug. 5, after market close. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 9.63%. SOLV delivered a trailing four-quarter average earnings surprise of 8.94%.
Solventum Q2 Estimates
Currently, the Zacks Consensus Estimate for second-quarter revenues is pegged at $2.17 billion. The consensus mark for second-quarter earnings is pinned at $1.91 per share.
Solventum’s second-quarter performance is expected to have reflected continued strength in its commercial execution across the MedSurg, Dental and Health Information Systems segments. Contributions from the Acera acquisition and ongoing cost-saving initiatives are also likely to support results.
Reported revenues are expected to have benefited from more than $100 million of advanced customer orders ahead of the planned U.S. ERP cutover in the third quarter. However, management stated that this represents a timing shift rather than incremental demand, with the benefit expected to reverse mainly in the third quarter. The company maintained its full-year guidance despite the sales phasing.
Tariff-related headwinds are expected to remain a drag. Nonetheless, savings from the Transform for the Future program and other productivity initiatives are likely to have supported margin expansion.
Segmental Overview
Solventum’s MedSurg segment is expected to have maintained healthy momentum in the second quarter. Growth is likely to have been driven by Advanced Wound Care, supported by continued demand for negative pressure wound therapy, including V.A.C. Peel and Place Dressing. The Acera acquisition is also expected to have contributed to reported growth as integration progresses. Infection Prevention and Surgical Solutions is likely to have benefited from strong demand for Tegaderm CHG and recent sterilization product launches. Reported growth may also have been aided by customer orders pulled forward ahead of the planned U.S. ERP cutover.
The Dental Solutions business is expected to have delivered another solid quarter. Performance is likely to have been supported by continued demand for the Clarity portfolio, Filtek Easy Match and Clinpro Clear products, along with stronger commercial execution and improved product availability. Similar to Infection Prevention, reported sales are also expected to have benefited from advanced customer orders ahead of the planned U.S. ERP cutover.
The Health Information Systems segment is expected to have continued its steady growth trajectory. Demand for Revenue Cycle Management solutions and increasing adoption of autonomous coding are likely to have remained key growth drivers. The company's international expansion and healthy backlog conversion are also expected to have supported segment performance. Weakness in Clinician Productivity Solutions is likely to have remained a partial offset.
On the operational front, investors are likely to watch progress on the company's separation from 3M and the upcoming U.S. ERP cutover. Management expects more than $100 million of sales to shift into the second quarter due to advance customer orders, with the benefit reversing mainly in the third quarter. Meanwhile, tariff headwinds are expected to persist. Even so, savings from the Transform for the Future program, portfolio optimization initiatives and productivity improvements are expected to continue supporting margins.
Earnings Beat Unlikely
Our proven model does not predict an earnings beat for Solventum this time around. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP:Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% for Solventum.
You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank:Solventum currently has a Zacks Rank #2.
Solventum Corporation Price and EPS Surprise
Solventum Corporation price-eps-surprise | Solventum Corporation Quote
Stocks Worth a Look
Here are some stocks worth considering from the broader medical sector, as these have the right combination of elements to post an earnings beat this reporting cycle.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Aug. 11. You can see the complete list of today’s Zacks #1 Rank stocks here.
CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter earnings per share (EPS) indicates an improvement of 16.4% from the year-ago reported figure.
Cencora (COR - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank of 2 at present. The company is scheduled to release third-quarter fiscal 2026 results on Aug. 5.
COR’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 1.59%. The Zacks Consensus Estimate for COR’s fiscal third-quarter EPS implies an improvement of 9.3% from the year-ago reported figure.
Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank #2 at present.
A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS calls for an improvement of 8% from the year-ago reported figure.